Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
A summary of representative PARP inhibitors in clinical development by route of administration and current clinical status.
| Agent | Company | Route of Administration | Clinical Status |
|---|---|---|---|
| Olaparib/(AZD2281) | AstraZeneca/KuDOS | Oral | Phase 1 and 2 |
| Veliparib/(ABT-888) | Abbott | Oral | Phase 1 and 2 |
| BS1-201 | BiPar/SanofiAventis | IV | Phase 2 and 3 |
| AG014699 | Pfizer | IV | Phase 1 and 2 |
| MK482 | Merck | Oral | Phase 1 |
| INO-1001 | Inotek | IV | Phase 1 |
| CEP9272 | Cephalon | Oral | Phase 1 |
